| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
DAGLβ (diacylglycerol lipase-β). DAGLβ is a serine hydrolase that produces the endocannabinoid 2-arachidonoylglycerol (2-AG) from diacylglycerol. KT109 shows ~60-fold selectivity for DAGLβ over DAGLα. The main off-target is ABHD6 (IC50 = 16 nM).
|
|---|---|
| ln Vitro |
KT109 inhibits DAGLβ with an IC50 of 42 nM. It has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows negligible activity against FAAH, MAGL, and ABHD11. The main off-target inhibition against ABHD6 has an IC50 of 16 nM.
|
| ln Vivo |
KT109-treated wild-type mice displayed reductions in LPS-induced allodynia similar to DAGL-β (-/-) mice. This confirms that the in vivo effects of KT109 are mediated through DAGLβ inhibition. Detailed pharmacodynamic effects in additional animal models have not been extensively reported.
|
| Enzyme Assay |
DAGLβ enzymatic activity assay: Recombinant human or mouse DAGLβ is incubated with varying concentrations of KT109 and a fluorogenic substrate (e.g., a diacylglycerol analogue or 4-nitrophenyl butyrate) in assay buffer (50 mM HEPES pH 7.4, 100 mM NaCl, 2 mM CaCl₂, 0.1% Triton X-100) at 37°C for 30-60 min. The reaction product is measured by fluorescence or absorbance. IC50 values are calculated.
|
| Cell Assay |
Endocannabinoid measurement in cells: Cells (e.g., Neuro2A or primary neurons) are treated with KT109 at varying concentrations (1 nM - 10 µM) for 30-60 min. Lipids are extracted, and 2-AG levels are measured by LC-MS/MS. The inhibition of DAGLβ-mediated 2-AG production is calculated. Selectivity is assessed by measuring other lipid species.
|
| Animal Protocol |
LPS-induced allodynia model in mice: Mice are treated with KT109 (route and dose to be determined) prior to intraplantar injection of LPS. Mechanical allodynia is assessed using von Frey filaments. Paw withdrawal thresholds are measured at various time points. KT109-treated mice show reductions in allodynia similar to DAGL-β knockout mice.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data has been published in the available literature. KT109 has a molecular weight and formula consistent with small-molecule serine hydrolase inhibitors. Comprehensive PK parameters such as bioavailability, half-life, and plasma protein binding remain to be characterized. The compound is available as a research reagent.
|
| Toxicity/Toxicokinetics |
No toxicity data has been published in the available literature. KT109 is for research use only. Standard laboratory safety practices should be followed when handling this compound. As a DAGLβ inhibitor, potential effects on endocannabinoid signaling should be considered.
|
| References | |
| Additional Infomation |
KT109 is a potent, selective DAGLβ inhibitor with an IC50 of 42 nM and ~60-fold selectivity over DAGLα. It shows negligible activity against FAAH, MAGL, and ABHD11. KT109 reduces LPS-induced allodynia in mice. The compound is a valuable tool for studying DAGLβ function in the endocannabinoid system. No clinical trials or approved上市 status have been reported.
|
| Molecular Formula |
C27H26N4O
|
|---|---|
| Molecular Weight |
422.532
|
| Exact Mass |
422.21
|
| CAS # |
1402612-55-8
|
| PubChem CID |
53364540
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
637.3±53.0 °C at 760 mmHg
|
| Flash Point |
339.3±30.9 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.653
|
| LogP |
5.23
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
593
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JKJMWHULJIOKPJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H26N4O/c32-27(30-18-8-7-13-25(30)19-21-9-3-1-4-10-21)31-20-26(28-29-31)24-16-14-23(15-17-24)22-11-5-2-6-12-22/h1-6,9-12,14-17,20,25H,7-8,13,18-19H2
|
| Chemical Name |
(2-benzylpiperidin-1-yl)-[4-(4-phenylphenyl)triazol-1-yl]methanone
|
| Synonyms |
KT 109; KT-109; KT109
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~236.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3667 mL | 11.8335 mL | 23.6670 mL | |
| 5 mM | 0.4733 mL | 2.3667 mL | 4.7334 mL | |
| 10 mM | 0.2367 mL | 1.1833 mL | 2.3667 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
